Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 236

Sort by

Sort Order Select

Journal Articles

Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Ting Zhang, Xu Shen, Yuanyuan Jin, Xin Cheng, Yuan Xia, Jianyong Li, Lijuan Chen

Blood (2025) 146 (Supplement 1): 2144.

https://doi.org/10.1182/blood-2025-2144

Published: 2025

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone

Yawen Zhang, Chengtao Qin, Yuemin Gong, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2025-2880

Published: 2025

Journal Articles

Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia

Chengtao Qin, Yawen Zhang, Yuemin Gong, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 6431.

https://doi.org/10.1182/blood-2025-6431

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Zhongxun Shi, Fei Huang, Yu Chen, Chun Qiao, Rong Wang, Yan Wang, Jianyong Li, Lei Fan, Wenyi Shen

Blood (2025) 146 (Supplement 1): 7362.

https://doi.org/10.1182/blood-2025-7362

Published: 2025

Journal Articles

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Blood (2025) 146 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2025-1824

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

The improvement of renal function by complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria

Chengtao Qin, Yuemin Gong, Yawen Zhang, Ting Zhang, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2025-2892

Published: 2025

Journal Articles

Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study

Wenyu Shi, Huayuan Zhu, Jianyong Li, Xiaoyan Xie, Xuzhang Lu, Lei Cao, Miao Sun, Yi Xia

Blood (2025) 146 (Supplement 1): 5477.

https://doi.org/10.1182/blood-2025-5477

Published: 2025

Journal Articles

Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns

Jinhua Liang, Yi-Fan Wu, Yi-Lun Ji, Liu-Qing Zhu, Li Wang, Jianyong Li, Xu Wei

Blood (2025) 146 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2025-1889

Published: 2025

Journal Articles

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

Guangsheng He, Yuemin Gong, Jianyong Li, Wenwei Zhu, Jingnan Sun, Chuan He, Wei Zhang, Cuicui Han, Jie Yang, Heng Liu

Blood (2025) 146 (Supplement 1): 983.

https://doi.org/10.1182/blood-2025-983

Published: 2025

Journal Articles

Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Keshu Zhou, Hongyun Xing, Qingliang Teng, Wuping Li, Yafei Wang, Feng Zhu, Zhengming Jin, Li Zhiming, Guifang Ouyang, Fang Xu, Shihua Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 4627.

https://doi.org/10.1182/blood-2024-202814

Published: 2024

Journal Articles

CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

Piers E.M. Patten, Arnon P. Kater, Jennifer A. Woyach, Jianyong Li, Talha Munir, Tommi Salmi, Patrick Phuong, Tian Tian, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 3257.1.

https://doi.org/10.1182/blood-2024-198737

Published: 2024

Journal Articles

Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort

Jinhua Liang, Yi-fan Wu, Jun-heng Liang, Yue Li, Xin-Yu Zhang, Hao-Rui Shen, Jiazhu Wu, Liu qing Zhu, Hua Yin, Li Wang, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 576.

https://doi.org/10.1182/blood-2024-194820

Published: 2024

Journal Articles

Role and Mechanisms Exploration of Histamine and Its Receptors in the Progression of Peripheral T-Cell Lymphoma

Hui Jin, Ling Wang, Yimin Ren, Zijuan Wu, Wenyu Shi, Jianyong Li

Blood (2024) 144 (Supplement 1): 4378.

https://doi.org/10.1182/blood-2024-211896

Published: 2024

Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2024-198296

Published: 2024

Journal Articles

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Jinhua Liang, Hao-Rui Shen, Hua Yin, Jiazhu Wu, Yue Li, Li Wang, Jianyong Li, Liang Wang, Xu Wei

Blood (2024) 144 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2024-203071

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Acalabrutinib in Chinese Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 24-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Shenmiao Yang, Haiwen Huang, Keshu Zhou, Xielan Zhao, Yanqiu Han, Lindong Li, Yujie Wang, Xiaofeng Liu, Jianyong Li

Blood (2024) 144 (Supplement 1): 6767.

https://doi.org/10.1182/blood-2024-193416

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone

Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

The improvement of renal function by complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria

Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study

Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort

Role and Mechanisms Exploration of Histamine and Its Receptors in the Progression of Peripheral T-Cell Lymphoma

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK/T Cell Lymphoma

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Acalabrutinib in Chinese Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 24-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only